source
- Kolon’s cell-based gene therapy misses key endpoints in phase 3 osteoarthritis trialKolon TissueGene reported that its phase 3 study of TG‑C, a cell‑based gene therapy for knee osteoarthritis, failed to meet its co‑primary endpoints. Patients receiving the therapy showed no statis…
- Latigo Biotherapeutics plans IPO to fund phase 3 trials of non-opioid pain drug LTG-001Latigo Biotherapeutics announced it is preparing an initial public offering to raise capital for its clinical-stage, non-opioid pain management pipeline. The company highlighted its oral Nav1.8 in…